Diversify Advisory Services LLC Acquires New Position in Becton, Dickinson and Company $BDX

Diversify Advisory Services LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,472 shares of the medical instruments supplier’s stock, valued at approximately $552,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the period. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new position in Becton, Dickinson and Company during the second quarter worth about $29,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BDX. Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Bank of America decreased their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Trading Up 0.1%

NYSE:BDX opened at $187.79 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The business’s 50-day simple moving average is $160.66 and its 200-day simple moving average is $160.91. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $190.01. The stock has a market capitalization of $51.74 billion, a PE ratio of 56.56, a price-to-earnings-growth ratio of 13.22 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the business earned $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 11,779 shares of company stock valued at $1,974,669. 0.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.